Targets significantly affected by both diseases (cancerand NAFLD) were CYP3A4, FMO3, UGT2B7, OATP2B1, EPHX1, and CES1. This evidence concerns the gene FMO3 and metabolic dysfunction-associated steatotic liver disease.